Objective To compare the pulmonary function, measured at birth and at hospital discharge, of infants whose mothers had been randomized to a single rescue course of antenatal steroids versus those whose mothers had been randomized to placebo.
Conclusions
Rescue antenatal steroids significantly increased Crs measured within 72 hours of birth, and this increase was sustained until hospital discharge. Preterm infants in the placebo group demonstrated a decreased initial Crs compared with the rescue antenatal steroids group, but achieved a comparable Crs by the time of discharge.
(J Pediatr 2017;181:62-6).
Trial registration ClinicalTrials.gov: NCT00669383. P reterm infants exhibit respiratory morbidities as a result of architectural and functional immaturities of the lung. Previous meta-analyses have definitively shown that a single course of antenatal steroids administered before preterm delivery at ≤34 weeks' gestation improves a host of neonatal outcomes. 1 These benefits are evident in both pulmonary function, with improved functional residual capacity (FRC) and passive respiratory compliance (Crs), 2 and clinical outcomes, with reduced rates of neonatal death, respiratory distress syndrome (RDS), intraventricular hemorrhage, and necrotizing enterocolitis, along with decreased durations of mechanical ventilation and oxygen therapy. 1 Given these clear benefits, treatment of women at risk for preterm delivery at ≤34 weeks' gestation with a single course of antenatal steroids remains the standard of care. 3 Complicating matters, however, is the fact that the beneficial effects of antenatal steroids are time-limited. The improvements in Crs and FRC are clearest in infants born 1-7 days after the first maternal antenatal steroid dose, and wane thereafter. 4 Ideally, all preterm infants would be delivered within this short window of maximal benefit, but accurately predicting the timing of preterm deliveries is difficult. As a result, some women treated with an initial course of antenatal steroids remain undelivered beyond this window of maximal benefit, but remain at risk for preterm delivery. The safety and efficacy of repeated courses of antenatal steroids remains an area of active investigation.
We recently reported that a single rescue course of antenatal steroids significantly increases the initial Crs and decreases the need for oxygen in treated preterm infants compared with controls. 5 In a concurrent similarly designed blinded study of 437 randomized patients, Garite et al reported improvement in a composite neonatal outcome (including RDS, oxygen requirement at 30 days, grade III-IV intraventricular hemorrhage, culture-proven sepsis, periventricular leukomalacia, necrotizing enterocolitis, and perinatal death) without short-term risk. 6 These studies provide evidence that rescue antenatal steroids can 
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significantly improve initial pulmonary mechanics and shortterm neonatal outcomes. Concerns remain about the potential negative effects on pulmonary function and lung growth after rescue antenatal steroids and the resultant effect on the trajectory of infant pulmonary function. A growing body of evidence demonstrates that lung function tracks along trajectories that are established in early childhood, and that these early trajectories are predictive of lung performance in early adulthood, 7, 8 but little is known about the early lung trajectories of infants born prematurely. 9 The objective of the present study was to compare the pulmonary function at birth and discharge of preterm infants randomized to a rescue course of antenatal steroids versus placebo. Because antenatal steroids have been shown to have the physiological effect of inducing surfactant production in the lung before a preterm delivery, 4 we hypothesized that the infants in the rescue antenatal steroids group would maintain a stable Crs level through discharge, and the Crs of the placebo-treated infants would increase during hospitalization to the point where there would be no difference in Crs between the 2 groups at discharge.
Methods
This study is an extension of a previously published prospective, randomized, placebo-controlled study of the impact of rescue antenatal steroids on pulmonary mechanics measured after delivery (ClinicalTrials.gov: NCT00669383). 5 In brief, the study was conducted at the neonatal intensive care units at Oregon Health & Science University (Portland, Oregon) and Sacred Heart Hospital (Pensacola, Florida). Randomization was stratified by gestational age at rescue antenatal steroid dosing (≤28 vs >28 weeks' gestation) and by multiple gestation (twins vs singletons). The study was approved by the Institutional Review Boards at each institution, and informed consent was obtained for each enrolled patient.
Pregnant women were recruited who met the following inclusion criteria: gestation between 26 and <34 weeks at the time of enrollment, ongoing risk of threatened preterm delivery as determined by a care provider, ≥14 days after receipt of an initial course of antenatal steroids, and provision of informed consent. Exclusion criteria included multiple gestation greater than twins, chorioamnionitis, insulin-dependent diabetes mellitus, major chromosomal or fetal abnormality, chronic steroid use during pregnancy, and an initial course of antenatal steroids administered at <24 weeks' gestation.
Women enrolled in the study were randomized to the rescue antenatal steroids arm (given two 12 mg intramuscular injections of betamethasone [Celestone Soluspan; Shering-Plough, Kenilworth, New Jersey]) or the placebo arm (given two 25 mg intramuscular injections of cortisone acetate, an inactive steroid indistinguishable in appearance from betamethasone) at 24-hour intervals.
Within 72 hours of birth, pulmonary function tests (PFTs) were performed to measure Crs, FRC, and Rrs (passive respiratory resistance). These measurements were repeated just before hospital discharge, usually at 34-36 weeks postmenstrual age.
All pulmonary function measurements were obtained using a computerized infant pulmonary function cart (SensorMedics 2600; Sensor-Medics, Yorba Linda, California) via mask or endotracheal tube. Tests were done with the infant supine and quietly asleep and were performed within 72 hours of birth (and before surfactant delivery, if required) and again near the time of discharge. Crs and Rrs were measured using the singlebreath occlusion technique to induce the Hering-Breuer reflex, as described previously.
2,4,10,11 Acceptable measurements required a stable end-expiratory baseline, plateau pressure >100 ms and varying by <0.125 cm H2O, appropriate flowvolume loops by visual inspection, and at least 10 breaths with a measured coefficient of variation <20% in accordance with standard international guidelines. [12] [13] [14] FRC was measured using the nitrogen washout technique. 2, 15, 16 After creating a calibration curve for each patient, the fraction of inspired oxygen (FiO2) was increased from baseline to 100% at end expiration. The curve was then used to correlate the nitrogen washout to the infant's FRC. The FRC accounts for dead space and is corrected for temperature, pressure, humidity, and the infant's weight. Acceptable measurements were obtained on a quietly sleeping, supine infant with testing initiated at end expiration, had no evidence of leak on tracing of the washout, and demonstrated consistency, with a coefficient of variation of <10% on at least 3 measurements.
Anthropometric measurements (weight, head circumference, and length) obtained at birth and at hospital discharge were compared in the 2 groups, and corresponding z-scores for these measurements were calculated. 17 Clinical variables, including surfactant administration, diagnosis of RDS (defined as clinical signs of respiratory distress with radiographic appearance and the need for supplemental oxygen with an FiO2 >0.21), respiratory distress with FiO2 requirement ≥0.30 or ≥0.40 at 24 hours of age, days on mechanical ventilation, and days on supplemental oxygen, were compared as well.
Statistical Analyses
Our analysis was performed on an intention-to-treat basis. For continuous variables, means were compared using the independent-samples Student t test. For categorical variables, the 2 groups were compared using the c 2 test and the Fisher exact test, as appropriate. P values and 95% CIs for the primary outcomes were determined using linear mixed modeling to account for the nonindependence of covariates among twins and also to account for additional confounders. 18 This analysis was performed using the same model, which adjusts for covariates including gestational age at birth, twin gestation, maternal smoking, rupture of membranes, and gestational diabetes, applied in a previous study of data from this dataset. 5 Analyses were performed using SPSS for Windows version 21 (IBM, Armonk, New York) and SAS 9.1.3 (SAS Institute, Cary, North Carolina). participate in the study, 27 declined participation and 23 showed no further evidence of preterm labor. The remaining 85 women were randomized to the rescue antenatal steroids arm (44 women) or the placebo arm (41 women). A total of 113 infants were born to these women and were included in the study, 56 from the rescue antenatal steroids arm and 57 from the placebo arm (Figure 1 ; available at www.jpeds.com). The average gestational age at birth for the entire cohort was 32.1 weeks (30.9 weeks for infants at ≤34 completed weeks gestation), and the average age at discharge was 36.3 weeks. The average time between the initial course of antenatal steroids and treatment with rescue antenatal steroids or placebo was 22.8 days, and the average time between treatment with rescue antenatal steroids or placebo and delivery was 15.4 days (Table) . In the rescue arm, 86.4% of the women (38 of 44) received a full 2-dose course of rescue antenatal steroids.
Results

As
We previously reported a significantly higher mean Crs at birth in the rescue antenatal steroids group compared with the placebo group (1.21 vs 1.01 mL/cm H2O/kg; P = .043). 5 Here we report that mean Crs at discharge was similar in the 2 groups (1.18 vs 1.22 mL/cm H2O/kg; P not significant). Mean FRC was similar in the 2 groups at birth (24.8 vs 22.0 mL/kg) and at discharge (24.9 vs 24.7 mL/kg), as was mean Rrs at birth (0.075 vs 0.083 cm H2O /mL/s) and at discharge (0.063 vs 0.064 cm H2O/mL/s) (Figure 2) .
For infants born at ≤34 completed weeks gestation, mean Crs at birth was significantly higher in the rescue antenatal steroids group compared with the placebo group (1.17 vs 0.90 mL/ cm H2O/kg; P = .0395), but mean Crs at discharge was similar in the 2 groups (1.14 vs 1.11 mL/cm H2O/kg; P not significant). Mean FRC was similar in the 2 groups at birth (24.3 vs 21.1 mL/kg) and at discharge (24.6 vs 24.0 mL/kg), as was mean Rrs at birth (0.077 vs 0.086 cm H2O /mL/s) and at discharge (0.064 vs 0.064 cm H2O /mL/s) (Figure 2) .
Discussion
Our findings demonstrate improved Crs in the rescue antenatal steroids group that was sustained from delivery until discharge in infants randomized to a single rescue course of antenatal steroids vs placebo. At the time of hospital discharge (34-36 weeks of corrected gestational age), there was no significant difference in Crs between the rescue antenatal steroids and placebo groups.
In previous work, we showed that compared with placebo, rescue antenatal steroids improved Crs at birth by 20% in our entire cohort and by 30% in the infants born at ≤34 weeks gestation. 5 Infants treated with rescue antenatal steroids also had decreased oxygen need. We found that this benefit for respiratory compliance was most evident in infants born at ≤34 weeks gestation, and that these more preterm infants also received important clinical benefits, including a lower risk of RDS. 5 In the present study, we built on our previous results to show that the increased Crs seen after rescue antenatal steroid therapy was both immediate (1.21 vs 1.01 mL/cm H2O/kg at birth; P < .05) and sustained until discharge. This early benefit was even greater for infants at ≤34 completed weeks gestation in the rescue antenatal steroids group (1.17 vs 0.90 mL/cm H2O/kg) and was similarly sustained until discharge. In the placebo group, the mean Crs was 1.01 mL/cmH2O/kg initially and increased to 1.22 mL/ cmH2O/kg at discharge, representing an approximate 20% increase over the course of hospitalization, which is also likely clinically significant. In this randomized trial, there were no statistical differences in FRC or Rrs between the 2 groups at delivery or discharge. These data show that rescue antenatal steroids provide an immediate increase in Crs at birth to a level not achieved in the placebo group until later in their hospital course, and that this benefit in pulmonary function comes with a reduced need for supplemental oxygen and a lower risk of RDS. This study is of particular importance as it relates to concerns regarding the safety of repeat courses of antenatal steroids. Previous studies in monkey and lamb models have associated the use of repeat courses of antenatal steroids with arrest of the normal program of alveolar septation, [19] [20] [21] raising concerns that the early benefits might be offset by long-term deleterious consequences to pulmonary function. As we reported previously, 5 Crs measured within 72 hours of birth is improved by a single rescue course of antenatal steroids. We now report that by the time of discharge, there was no significant difference in Crs, FRC, or Rrs between the 2 randomized groups. Thus, the early benefits of the rescue antenatal steroids course do not appear to be offset by deficits in pulmonary function at the time of discharge. Furthermore, as we have reported previously, this single-course rescue antenatal steroids regimen is not associated with differences in standardized z-scores for birth weight, birth head circumference, or birth length, although the initial study was not powered to reveal differences in these important anthropometric outcomes. 5 Taken together, the foregoing findings suggest that rescue antenatal steroids confer an immediate increase in respiratory compliance that is physiological but not supraphysiological in degree, and lend support to the safety of a single repeat course of antenatal steroids for preterm deliveries. We speculate that the initial increase in Crs in the rescue antenatal steroids group may be due to reinduction of the enzyme system responsible for surfactant production. 4 Although there was a trend for a higher FRC in the antenatal steroids group, it did not meet statistical significance, and we speculate that the FRC measurements reflect structural changes that persist after a single course of antenatal steroids. These findings also suggest that a limited course of rescue antenatal steroids, similar to the single 2-dose regimen used in this study, might provide an optimal initial benefit to pulmonary function with minimal alteration of growth. A direct comparison of different rescue antenatal steroids regimens is needed to test this hypothesis fully, however.
A growing body of evidence suggests that PFT results in early childhood are predictive of future lung function. Stern et al reported that among healthy term newborns tested shortly after birth, those in the lowest quartile for maximal flow at FRC also had lower measurements of forced expiratory flow at multiple time points up to 22 years of age. 7 Belgrave et al reported a similar effect in measurements of specific airway resistance at age 3 years to predict specific airway resistance at age 11 years. 8 These prospective cohort studies suggest that trajectories established early in childhood predict future lung function.
Building on the aforementioned observational studies, our interventional study demonstrates that rescue antenatal steroids induced a clear and sustained increase in Crs in the study group, and that the placebo group, only remotely treated with antenatal steroids, had a lower initial Crs that increased over the hospital course. Although our data in this study are focused on only 2 time points-birth and hospital discharge-they suggest that rescue antenatal steroids can alter the trajectory of Crs in the premature lungs in the early neonatal period. In light of the evidence that early lung trajectories are predictive of later lung function, we speculate that these early changes in Crs seen after rescue antenatal steroids might change the trajectory of the premature infant's pulmonary function, which could lead to improved long-term pulmonary outcomes. This study's strengths include its randomized, placebocontrolled design, use of a limited 2-dose course of antenatal steroids, and use of objective pulmonary function data obtained by a single respiratory therapist to augment the data provided by similar studies with clinical outcomes. Given the increasing evidence indicating that individuals continue to track along PFT percentiles established very early in life, it is Comparison of A, Crs (mL/cm H2O/kg), B, FRC (mL/ kg), and C, Rrs (cm H2O/mL/s) at birth and discharge for infants in the entire cohort (left) and for the subset born at ≤34 completed weeks gestation (right). **P <.05. Error bars represent standard error.
important to quantify sequential PFTs to track therapeutic responses, particularly in the critical periods of rapid lung growth in infancy. 7 Nonetheless, we recognize several aspects of our study population that may limit the applicability of this study. By design, all of the infants in this study had received a previous initial course of antenatal steroids, and the study did not include a group untreated with antenatal steroids. For this reason, the study's conclusions on pulmonary function are most relevant to infants treated antenatally with antenatal steroids. Similarly, the majority of the infants in this study were delivered at ≤34 weeks gestation, with an average gestational age at birth of 32.1 weeks. Although our PFT results are congruent with the clinical findings in other studies of rescue antenatal steroids, the average age in our dataset is somewhat older, and should be interpreted accordingly. Notably, the impact of rescue antenatal steroids on passive respiratory compliance was greatest in the subset of infants born at ≤34 weeks gestation, with an average gestational age at birth of 30.9 weeks. Finally, despite randomization, there were more maternal smokers in the rescue antenatal steroids arm than in the placebo arm. Maternal smoking is known to affect neonatal respiratory compliance, 22 and we adjusted for this and other variables in our statistical model.
This study provides a longitudinal perspective of the pulmonary function of infants treated with rescue antenatal steroids compared with placebo from the time of birth until hospital discharge. Rescue antenatal steroids confer significant, measurable benefits in pulmonary function that are immediate, physiological, and sustained throughout the initial hospitalization. Importantly, no differences in pulmonary function at discharge were seen between the infants treated with rescue antenatal steroids and those treated with placebo, providing evidence in support of the safe use of a single 2-dose regimen of rescue antenatal steroids, although the sample size is small. Serial measurements of pulmonary function though early childhood are needed to assess the effects of this early alteration in respiratory compliance trajectory on long-term pulmonary function and respiratory outcomes. ■ Submitted for publication May 11, 2016 
